Dyadic Updates Market on Recent Scientific Achievements
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Clinical Trial
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...
Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of...
Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract Infections
Marks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicineRESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) --...
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD...
Salarius Pharmaceuticals CEO Issues Letter to Stockholders
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients...
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN...
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II
Las Vegas, NV, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative...
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial
ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck’s KEYTRUDA® (pembrolizumab) for treatment of...
Amryt Announces New Patent for Mycapssa®
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage...
Smart Immune Bolsters Management Team with Medical and Technical Appointments
Smart Immune pic Dr Pierre Heimendinger and Dr Frederic Lehmann, CTO and CMO of Smart Immune. Smart Immune Bolsters Management...
ObsEva Announces Progress on Restructuring Initiatives
$7.6 million annual savings expected via reduction-in-force currently underway$6.2 million savings expected from assignment of legacy linzagolix program contracts to...
BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022
Plinabulin rapidly (within 24 hours) mitigates chemotherapy-induced myelosuppression by protecting bone marrow granulocyte-monocyte progenitor (GMP) stem cellsNEW YORK, Sept. 13,...
Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss
-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the...
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
Award to fund clinical study of Marker’s multi-antigen targeted T cell therapy for the treatment of post-transplant AML patients with...
Shape Therapeutics named one of Fierce Biotech’s “Fierce 15” Companies of 2022
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), the RNA technology company advancing programmable medicine, today announced...
Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for...